Key Highlights
- Aptevo Therapeutics (NASDAQ:APVO) reported a third-quarter net loss of USD 6.5 million, down from USD 7.5 million a year earlier, as general and administrative costs fell to USD 2.9 million from USD 3.6 million.
- Cash and cash equivalents were USD 8.3 million at September 30, 2026, against USD 21.6 million at December 31, 2025, after nine-month operating cash use of USD 19.1 million.
- Management concluded that substantial doubt exists about the ability to continue as a Going Concern for the year after the filing date, and the company has 3,464,923 shares outstanding.
- In the mipletamig triplet, 11 of 14 evaluable TP53-mutated AML patients (79%) reached complete remission or remission with incomplete count recovery, with dose optimization targeted by year-end 2026.
Smaller Loss, but a Thin Cash Balance
Aptevo Therapeutics (NASDAQ:APVO) filed its Quarterly Report on November 16, 2026 for the period ended September 30. Net loss was USD 6.5 million, compared with USD 7.5 million in the third quarter of 2025, and the loss per common share, after deemed dividends, was USD 5.19 against USD 40.13. Research and Development spending slipped to USD 3.7 million from USD 4.0 million, and general and administrative expense fell to USD 2.9 million from USD 3.6 million on lower employee costs. A deemed Dividend of USD 2.8 million lifted the loss attributable to common stockholders to USD 9.3 million. Aptevo is a clinical-stage biotechnology company that builds cancer immunotherapies on its ADAPTIR and ADAPTIR-FLEX protein platforms. The lead candidate, mipletamig, is a CD123xCD3 T cell engager in a Phase 1b and 2 program for frontline acute myelogenous leukemia.
Nine-Month Burn and the Going Concern Warning
For the nine months, the net loss was USD 19.6 million against USD 20.2 million a year earlier, and Operating Activities used USD 19.1 million of cash. Financing brought in USD 5.9 million, well below the USD 32.7 million raised in the same period of 2025. Cash therefore dropped by USD 13.3 million, to USD 8.3 million. Management and the board concluded that substantial doubt exists about the ability to continue as a going concern, citing recurring losses and negative operating cash flow. The accumulated Deficit stood at USD 297.6 million, and the company said it will need to raise additional funds.
Financing Tools, Listing Rules and Clinical Milestones
Funding sources include a private Placement and Warrant inducement that produced about USD 4.5 million gross, with new warrants that could add up to USD 22.5 million if exercised. Two standby Equity purchase agreements with Yorkville remain, and about USD 8.0 million was still available under the first one at quarter end. The company also reported a reimbursement grant of up to about USD 1.5 million for the APVO451 solid tumor program. A 1-for-18 Reverse Stock Split took effect on December 29, 2025, and the filing warns that a closing bid below USD 1.00 for 30 consecutive Business days could mean immediate delisting, since a cure period would not apply. On the clinical side, 13 of 14 evaluable TP53-mutated patients (93%) showed clinical benefit, and 10 of 47 evaluable frontline patients proceeded to stem cell transplant.
Where Things Stand
Cash is tight rather than comfortable. Aptevo Therapeutics (NASDAQ:APVO) ended September with USD 8.3 million, spent USD 19.1 million of operating cash in nine months, and carries a formal going concern warning. The smaller quarterly loss came from lower general and administrative costs, not from new funding. Calculated from the filing, USD 13.3 million left the Balance Sheet since December 31. What matters next is whether warrant exercises and the standby agreements can bridge to the planned Phase 1b dose optimization at year-end 2026 and the regulatory interaction in the first half of 2027.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...